Show simple item record

dc.contributor.authorSepúlveda, Maria
dc.contributor.authorLlufriu, Sara
dc.contributor.authorMartínez-Hernández, Eugenia
dc.contributor.authorCatalà Sabaté, Martí
dc.contributor.authorArtola, Montse
dc.contributor.authorHernando, Ana
dc.contributor.authorMontejo, Carmen
dc.contributor.authorPulido-Valdeolivas, Irene
dc.contributor.authorMartinez-Heras, Eloy
dc.contributor.authorGuasp, Mar
dc.contributor.authorSolana, Elisabeth
dc.contributor.authorLlançó, Laura
dc.contributor.authorEscudero, Domingo
dc.contributor.authorAldea, Marta
dc.contributor.authorPrats Soler, Clara
dc.contributor.authorGraus Ribas, Francesc
dc.contributor.authorBlanco, Yolanda
dc.contributor.authorSaiz, Albert
dc.contributor.otherUniversitat Politècnica de Catalunya. Doctorat en Física Computacional i Aplicada
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament de Física
dc.coverage.spatialeast=2.1523118019104004; north=41.38944692070279; name=Carrer de Casanova, 141, 08036 Barcelona, Espanya
dc.date.accessioned2021-02-05T11:12:43Z
dc.date.available2021-02-05T11:12:43Z
dc.date.issued2021-01-27
dc.identifier.citationSepúlveda, M. [et al.]. Incidence and impact of COVID-19 in MS. A survey from a Barcelona MS Unit. "Neurology-Neuroimmunology & Neuroinflammation", 27 Gener 2021, vol. 8, núm. 2, p. e954.
dc.identifier.issn2332-7812
dc.identifier.urihttp://hdl.handle.net/2117/336992
dc.description.abstractObjective: To investigate the incidence of coronavirus disease 2019 (COVID-19) in a single-center cohort of patients with MS and to explore the contribution of their comorbidities and therapies to the outcome. Methods: A cross-sectional mixed-method study was conducted involving an email-based, self-administered questionnaire sent on May 21, 2020, to 586 patients with MS followed at the MS Unit of Hospital Clinic, University of Barcelona, along with telephone interview, and review of electronic medical records until June 18, 2020. The cumulative incidence of confirmed COVID-19 (positive PCR or antibody test) and all COVID-19 cases (confirmed and suspected) from the start of the pandemic was compared with the population estimates for Barcelona. Results: A total of 407 patients (69.5%) completed the survey. Most of the responders (67%) were female. The responders had a median age of 48 years (range 19–86), relapsing-remitting disease (84%), at least 1 comorbidity (45%), and were on disease-modifying therapy (DMT; 74.7%). COVID-19 was confirmed in 5 patients (1.2%) and suspected in 46 (11.3%). The cumulative incidence of confirmed COVID-19 cases was similar to that of the general population but was almost 2-fold higher when all cases were considered (p < 0.001). Six patients (11.7%) were hospitalized, of which 5 had good recovery and 1 died. Hospitalized patients were more frequently male, had diabetes and had progressive forms of MS (p < 0.05). DMT was not associated with the risk of infection or the outcome. Conclusions: In the studied MS cohort, the incidence of COVID-19 was higher than that of the general population; however, most patients did not require hospitalization and had a good outcome despite the frequent presence of comorbidities and treatment with DMT.
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Spain
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectÀrees temàtiques de la UPC::Matemàtiques i estadística::Anàlisi numèrica::Modelització matemàtica
dc.subject.lcshEpidemics
dc.subject.lcshMultiscale modeling
dc.subject.lcshCOVID-19 (Disease)
dc.subject.otherDisease-modifying therapy
dc.subject.otherExpanded disability severity scale
dc.subject.otherSARS-CoV-2
dc.titleIncidence and impact of COVID-19 in MS. A survey from a Barcelona MS Unit.
dc.typeArticle
dc.subject.lemacEpidemies
dc.subject.lemacModelització en etapes múltiples
dc.subject.lemacCOVID-19 (Malaltia)
dc.contributor.groupUniversitat Politècnica de Catalunya. BIOCOM-SC - Grup de Biologia Computacional i Sistemes Complexos
dc.identifier.doi10.1212/NXI.0000000000000954
dc.description.peerreviewedPeer Reviewed
dc.relation.publisherversionhttps://nn.neurology.org/content/8/2/e954
dc.rights.accessOpen Access
local.identifier.drac30433042
dc.description.versionPostprint (published version)
local.citation.authorSepúlveda, M.; Llufriu, S.; Martínez-Hernández, E.; Català, M.; Artola, M.; Hernando, A.; Montejo, C.; Pulido-Valdeolivas, I.; Martinez-Heras, E.; Guasp, M.; Solana, E.; Llançó, L.; Escudero, D.; Aldea, M.; Prats, C.; Graus, F.; Blanco, Y.; Saiz, A.
local.citation.publicationNameNeurology-Neuroimmunology & Neuroinflammation
local.citation.volume8
local.citation.number2
local.citation.startingPagee954


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Spain
Except where otherwise noted, content on this work is licensed under a Creative Commons license : Attribution-NonCommercial-NoDerivs 3.0 Spain